Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
05
10
2021
pubmed:
21
1
2022
medline:
5
4
2022
entrez:
20
1
2022
Statut:
epublish
Résumé
Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson and Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S.
Identifiants
pubmed: 35045692
doi: 10.3324/haematol.2021.280154
pmc: PMC8968905
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
COVID-19 Vaccines
0
Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
947-957Références
Blood. 2021 Dec 2;138(22):2256-2268
pubmed: 34587242
Clin Med (Lond). 2021 Nov;21(6):e600-e602
pubmed: 34645700
N Engl J Med. 2021 Sep 30;385(14):1334-1336
pubmed: 34432977
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
J Proteome Res. 2020 May 1;19(5):2035-2042
pubmed: 32195589
Nature. 2021 Aug;596(7873):565-569
pubmed: 34233346
Blood. 2021 Oct 7;138(14):1269-1277
pubmed: 34280256
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19733-8
pubmed: 23091005
BMC Dev Biol. 2010 Jul 23;10:76
pubmed: 20653957
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Ann Intern Med. 2022 Jan 18;:
pubmed: 35038274
Vaccine. 2011 Jul 18;29(32):5267-75
pubmed: 21605614
J Phys D Appl Phys. 2019 Apr 17;52(16):163001
pubmed: 33191949
Clin Exp Immunol. 1990 Mar;79(3):367-73
pubmed: 2107990
MethodsX. 2021 May 01;8:101372
pubmed: 34430268
Acta Physiol (Oxf). 2017 May;220(1):167-173
pubmed: 27414464
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Clin Cancer Res. 2011 May 1;17(9):2734-43
pubmed: 21364033
Nat Methods. 2005 May;2(5):357-62
pubmed: 15846363
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Proteomics. 2019 Dec;19(23):e1900192
pubmed: 31532911
Sci Adv. 2021 Dec 03;7(49):eabl8213
pubmed: 34851659
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Sci Rep. 2019 Nov 29;9(1):17967
pubmed: 31784555